The European Medicines Agency, in cooperation with the European Center for Communicable Diseases, expressed their support for the recent steps taken by many Member States by giving different vaccines between the first and second doses, or between the full course and the booster dose, which many recent clinical studies have shown to provide higher immune protection than that. that arise from one type of vaccine.
With the aim of adding more flexibility to vaccination campaigns, the expert team of the two European bodies will publish today, Monday, a set of scientific evidence and technical recommendations about the combination of different vaccines against the virus during the first cycle or when giving the booster dose.
The recommendations include an explanation of the studies that showed that heterogeneous vaccination between the viral vector vaccine and the messenger RNA vaccine generates good levels of antibody and a higher cellular response than the heterogeneous vaccination, during the first cycle of vaccination or when the booster dose is given. As for the use of the viral vector vaccine as a second dose in the first cycle, or two different types of messenger RNA vaccines, the studies conducted so far are not sufficient to draw reliable scientific conclusions about it.
Experts say that as research continues for more evidence about the long-term safety and efficacy of heterogeneous vaccination and the extent of the immune protection it produces, it is clear that this vaccination provides more flexibility in scheduling vaccination campaigns, especially when specific vaccines are not available for any reason.
As for the immune response generated by heterogeneous vaccination, studies have shown that it is much higher than the response generated by homogeneous vaccination, especially in terms of the amounts of memory cells that play a primary role in the long-term immune response. It was also observed that heterogeneous vaccination generates a higher humoral immune response than homogeneous vaccination in some cases, but this aspect still needs further studies. Experts believe that if this conclusion is confirmed, the effectiveness of heterogeneous vaccination will be much higher than what studies have shown so far, according to Asharq Al-Awsat newspaper.
The experts conclude that based on the available data and the results of clinical studies, it can be said that giving a second dose of the messenger RNA vaccine to a person who has taken the first dose of the viral vector vaccine is a useful vaccine strategy from an immunological perspective and helps provide higher protection from infection and disease.
However, there is insufficient evidence so far about heterogeneous inoculation between two mRNA vaccines, although the available data suggest that it gives more flexibility and speed to vaccination campaigns when appropriate.
It should be noted that there are ongoing studies to determine the safety of this vaccination in terms of its effect on the incidence of inflammation of the heart muscle, which was observed in particular among adolescent males. Experts also mention that giving the second dose of the viral vector vaccine to someone who has taken the first dose of the messenger RNA vaccine is less effective than the opposite technique. As for the booster dose, all studies conducted so far have shown that giving an additional dose of the messenger RNA vaccine to those who took the first course of the viral vector vaccine, or a different dose of the same vaccine category, generates a higher immune protection compared to giving the dose The booster is from the same vaccine that was given in the first cycle, and possibly for longer.
The European Medicines Agency has called for strengthening efforts to develop drug treatments against “Covid-19”. In a joint statement with the coalition of drug regulatory bodies, she urged all concerned parties, including scientific research institutions, pharmaceutical companies, the medical community and agencies funding research and health studies, to redouble their efforts in order to reach as soon as possible the development and production of effective drugs against infection with the emerging corona virus and treating its symptoms. dangerous.
The Amsterdam-based agency said: “Vaccines are still the main weapon in the battle against the Covid pandemic today, but they are not enough, and we also need effective, safe and high-quality drugs to treat all symptoms of this disease in all population groups, including children and pregnant women, for years to come.”
Mixing Corona vaccines provides greater effectiveness
“All members of the coalition are committed to continuing efforts to facilitate approval requirements for drugs against (Covid) in order to increase the availability of complementary vaccine therapies, especially in low-income and poor countries,” said Emir Kok, executive director of the agency and chair of the International Alliance of Regulators. This joint statement on the importance of continuing to focus efforts on therapeutic drugs against “Covid” was issued at the conclusion of a series of meetings and intensive discussions between members of the International Alliance to accelerate efforts to develop these drugs and facilitate the conditions for approval of their use and distribution on a global scale.
In addition, the European Medicines Agency and the European Center for Communicable Disease Control and Prevention stressed the importance of accelerating the intensification of vaccination efforts and being guided by scientific recommendations to give booster doses of vaccines. In a joint statement, the two European bodies had expressed “deep concern over the recent developments in the European epidemiological scene, which for weeks has been recording a steady increase in the number of new infections and cases requiring hospital treatment, especially in countries that still have low rates of vaccine coverage.”